Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1514007 | 0.87 | DPP4 (0.53) | DPP4DPP7DPP8MEN1KMT2A | |
| SCHEMBL6638863 | 0.84 | DPP4 (0.53) | DPP4DPP7DPP8MEN1KMT2A | |
| SCHEMBL21521629 | 0.79 | DPP7 (0.52) | DPP4DPP7DPP8MEN1KMT2A | |
| SCHEMBL8003211 | 0.79 | DPP4 (0.47) | DPP4DPP7DPP8 | |
| SCHEMBL8312031 | 0.79 | DPP4 (0.60) | DPP4DPP7DPP8MEN1KMT2A | |
| SCHEMBL1726095 | 0.79 | DPP7 (0.50) | DPP4DPP7DPP8MEN1KMT2A | |
| SCHEMBL7367925 | 0.79 | DPP7 (0.47) | DPP4DPP7DPP8MEN1KMT2A | |
| SCHEMBL402113 | 0.78 | DPP7 (0.51) | DPP4DPP7DPP8MEN1KMT2A | |
| SCHEMBL6125342 | 0.77 | DPP4 (0.48) | DPP4DPP7DPP8MEN1KMT2A | |
| SCHEMBL402112 | 0.77 | DPP4 (0.51) | DPP4DPP7DPP8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130052239-A1 | Formulation | JOSHI YATINDRA (US) | 2013-02-28 | — | — | US | claimed |
| US-20110301172-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN | BURKEY BRYAN (US) | 2011-12-08 | — | — | US | claimed |
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | BURKEY BRYAN | 2009-10-08 | — | — | US | claimed |
| US-20080299190-A1 | Direct Compression Formulation and Process | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | claimed |
| US-20080193529-A1 | Direct Compression Formulation and Process | KOWALSKI JAMES | 2008-08-14 | — | — | US | claimed |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | HOLMES DAVID G | 2007-06-28 | — | — | US | claimed |
| EP-3366283-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| US-20140287040-A1 | Formulation | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140205663-A1 | Direct Compression Formulation and Process | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| US-20130052239-A1 | Formulation | JOSHI YATINDRA (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | KOWALSKI JAMES (US) | 2012-11-22 | — | — | US | disclosed |
| US-20110301172-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN | BURKEY BRYAN (US) | 2011-12-08 | — | — | US | disclosed |
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | BURKEY BRYAN | 2009-10-08 | — | — | US | disclosed |
| US-20080269311-A1 | Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors | VILLHAUER EDWIN BERNARD | 2008-10-30 | — | — | US | disclosed |
| US-20080221200-A1 | Combination of Organic Compounds | ALLISON MALCOLM | 2008-09-11 | — | — | US | disclosed |
| US-20080193529-A1 | Direct Compression Formulation and Process | KOWALSKI JAMES | 2008-08-14 | — | — | US | disclosed |
| US-20080038341-A1 | Free-flowing, cohesive tableting powder for direct compressed tablet; DPP-IV inhibitor and glitazone, in unit dosage form; acceptable dissolution profile; acceptable degrees of hardness, resistance to chipping, short disintegration time | KOWALSKI JAMES | 2008-02-14 | — | — | US | disclosed |
| US-20070293474-A1 | Combination of a DPP IV inhibitor and a cardiovascular compound | HOLMES DAVID G | 2007-12-20 | — | — | US | disclosed |
| US-20070264194-A1 | Peptides That Bind To Atherosclerotic Lesions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | HOLMES DAVID G | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299190-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 6/4885 |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | GIPR, DPP4, MC4R | DPP4 2/4885DPP7 9/4885DPP8 20/4885 |
| US-20080038341-A1 | Free-flowing, cohesive tableting powder for direct compressed tablet; DPP-IV inhibitor and glitazone, in unit dosage form; acceptable dissolution profile; acceptable degrees of hardness, resistance to chipping, short disintegration time | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20070264194-A1 | Peptides That Bind To Atherosclerotic Lesions | FABP3, CCL2, VCAM1 | DPP4 659/4885DPP7 651/4885DPP8 1189/4885 |
| US-20070293474-A1 | Combination of a DPP IV inhibitor and a cardiovascular compound | DPP4, DPP3, DPP9 | DPP4 1/4885DPP7 4/4885DPP8 5/4885 |
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | PPARG, DPP4, DPP3 | DPP4 2/4885DPP7 5/4885DPP8 7/4885 |
| US-20080193529-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20110301172-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN | PPARG, DPP4, DPP3 | DPP4 2/4885DPP7 5/4885DPP8 7/4885 |
| US-20080221200-A1 | Combination of Organic Compounds | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20140205663-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20140287040-A1 | Formulation | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20080269311-A1 | Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors | HTR4, DPP4, HTR3B | DPP4 2/4885DPP7 20/4885DPP8 23/4885 |
| US-20130052239-A1 | Formulation | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.